Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics has granted equity awards to six new employees as inducement for employment. The awards include 47,600 stock options with an exercise price of $5.73 per share and 42,710 restricted stock units (RSUs). The options have a 10-year term, vesting over four years with 25% vesting after one year and the remainder monthly over three years. The RSUs will vest in equal annual installments over four years starting January 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics ha concesso premi di equity a sei nuovi dipendenti come incentivo per l'assunzione. I premi includono 47.600 opzioni su azioni con un prezzo di esercizio di $5,73 per azione e 42.710 unità di azioni vincolate (RSU). Le opzioni hanno una durata di 10 anni, con un periodo di maturazione di quattro anni in cui il 25% si matura dopo un anno e il restante mensilmente nei tre anni successivi. Le RSU matureranno in rate annuali uguali per un periodo di quattro anni a partire dal 1 gennaio 2025. Questi premi sono stati concessi nell'ambito del Piano di Incentivazione Azionaria 2024 dell'azienda, in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
Verve Therapeutics ha otorgado premios en acciones a seis nuevos empleados como un incentivo para la contratación. Los premios incluyen 47,600 opciones sobre acciones con un precio de ejercicio de $5.73 por acción y 42,710 unidades de acciones restringidas (RSU). Las opciones tienen un plazo de 10 años, con un período de adquisición de cuatro años en el que el 25% se adquiere después de un año y el resto mensualmente durante tres años. Las RSU se adquirirán en cuotas anuales iguales durante cuatro años a partir del 1 de enero de 2025. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones de Inducción 2024 de la compañía, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Verve Therapeutics는 새로운 직원 여섯 명에게 고용 유인을 위한 주식 보상을 부여했습니다. 이러한 보상에는 47,600주식 옵션과 주당 $5.73의 행사 가격, 그리고 42,710개의 제한 주식 유닛(RSU)이 포함됩니다. 옵션의 유효 기간은 10년이며, 4년 동안 25%가 1년 후에 귀속되고 나머지는 3년 동안 매월 귀속됩니다. RSU는 2025년 1월 1일부터 시작하여 4년 동안 매년 같은 비율로 귀속됩니다. 이러한 보상은 회사의 2024 유인 주식 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)에 부합하여 이루어졌습니다.
Verve Therapeutics a accordé des attributions d'actions à six nouveaux employés en tant qu'incitation à l'embauche. Les attributions incluent 47,600 options d'achat d'actions avec un prix d'exercice de 5,73 $ par action et 42,710 unités d'actions restreintes (RSU). Les options ont une durée de 10 ans et sont acquises sur quatre ans, avec 25% qui s'acquièrent après un an et le reste mensuellement sur trois ans. Les RSUs seront acquises en versements annuels égaux sur quatre ans à partir du 1er janvier 2025. Ces concessions ont été faites dans le cadre du Plan d'Incentivation des Actions de 2024 de l'entreprise, conformément à la règle de cotation Nasdaq 5635(c)(4).
Verve Therapeutics hat sechs neuen Mitarbeitern Aktienvergütungen als Anreiz zur Einstellung gewährt. Die Vergütungen umfassen 47.600 Aktienoptionen mit einem Ausübungspreis von $5,73 pro Aktie und 42.710 eingeschränkten Aktieneinheiten (RSUs). Die Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre gewährt, wobei 25% nach einem Jahr und der Rest monatlich über drei Jahre fällig wird. Die RSUs werden in gleichen jährlichen Raten über vier Jahre ab dem 1. Januar 2025 fällig. Diese Zuwendungen wurden im Rahmen des Aktienoptionsplans zur Anwerbung 2024 des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- None.
- None.
BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company granted equity awards to six new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received stock options to purchase an aggregate of 47,600 shares of the company’s common stock and an aggregate of 42,710 restricted stock units (RSUs). The options have an exercise price of
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
What equity awards did Verve Therapeutics (VERV) grant to new employees on October 31, 2024?
What is the vesting schedule for VERV's October 2024 stock options grant?
How will the RSUs granted by VERV in October 2024 vest?
What is the exercise price of VERV's stock options granted on October 31, 2024?
